ES2634551T3 - Métodos para revestir una lente de contacto - Google Patents
Métodos para revestir una lente de contacto Download PDFInfo
- Publication number
- ES2634551T3 ES2634551T3 ES11763185.3T ES11763185T ES2634551T3 ES 2634551 T3 ES2634551 T3 ES 2634551T3 ES 11763185 T ES11763185 T ES 11763185T ES 2634551 T3 ES2634551 T3 ES 2634551T3
- Authority
- ES
- Spain
- Prior art keywords
- drug
- layer
- printing
- coating
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 191
- 238000000576 coating method Methods 0.000 title claims abstract description 138
- 239000011248 coating agent Substances 0.000 title claims description 122
- 239000003814 drug Substances 0.000 claims abstract description 549
- 229940079593 drug Drugs 0.000 claims abstract description 547
- 238000007639 printing Methods 0.000 claims abstract description 167
- 230000004888 barrier function Effects 0.000 claims abstract description 108
- 239000000654 additive Substances 0.000 claims abstract description 10
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 238000000151 deposition Methods 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims description 40
- 102000013138 Drug Receptors Human genes 0.000 claims description 35
- 108010065556 Drug Receptors Proteins 0.000 claims description 35
- 238000010146 3D printing Methods 0.000 abstract description 20
- 239000010410 layer Substances 0.000 description 318
- 239000000203 mixture Substances 0.000 description 120
- 239000011247 coating layer Substances 0.000 description 108
- 238000009472 formulation Methods 0.000 description 89
- 239000000463 material Substances 0.000 description 80
- 229920000642 polymer Polymers 0.000 description 74
- 238000005516 engineering process Methods 0.000 description 51
- 239000000178 monomer Substances 0.000 description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
- 239000000243 solution Substances 0.000 description 41
- 238000007641 inkjet printing Methods 0.000 description 32
- 239000002105 nanoparticle Substances 0.000 description 32
- 238000011282 treatment Methods 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 27
- 238000004806 packaging method and process Methods 0.000 description 25
- 238000006116 polymerization reaction Methods 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 239000003999 initiator Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000003287 optical effect Effects 0.000 description 20
- 229920001296 polysiloxane Polymers 0.000 description 20
- 235000014633 carbohydrates Nutrition 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 18
- 150000001720 carbohydrates Chemical class 0.000 description 18
- 150000005829 chemical entities Chemical class 0.000 description 17
- 238000012377 drug delivery Methods 0.000 description 17
- 238000013508 migration Methods 0.000 description 17
- 230000005012 migration Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 description 16
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 16
- -1 acetylene glycol Chemical compound 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 238000005538 encapsulation Methods 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 239000003732 agents acting on the eye Substances 0.000 description 12
- 229940023490 ophthalmic product Drugs 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000001723 curing Methods 0.000 description 10
- 239000002270 dispersing agent Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000000919 ceramic Substances 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000007648 laser printing Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000007651 thermal printing Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000010023 transfer printing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 208000010412 Glaucoma Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000000744 eyelid Anatomy 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 7
- 229920000058 polyacrylate Polymers 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920000515 polycarbonate Polymers 0.000 description 7
- 239000003505 polymerization initiator Substances 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 6
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 229960004605 timolol Drugs 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 5
- 230000002745 absorbent Effects 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 4
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010894 electron beam technology Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000010439 graphite Substances 0.000 description 4
- 229910002804 graphite Inorganic materials 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940099563 lactobionic acid Drugs 0.000 description 4
- 230000005499 meniscus Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 229920002721 polycyanoacrylate Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000003848 UV Light-Curing Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229920006397 acrylic thermoplastic Polymers 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 238000001311 chemical methods and process Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000003806 hair structure Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 125000000687 hydroquinonyl group Chemical class C1(O)=C(C=C(O)C=C1)* 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000002071 nanotube Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000010526 radical polymerization reaction Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 3
- 238000012719 thermal polymerization Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000007514 turning Methods 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical compound O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- RBFPEAGEJJSYCX-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CCOCCOCCOCCOC(=O)C(C)=C RBFPEAGEJJSYCX-UHFFFAOYSA-N 0.000 description 2
- NECRQCBKTGZNMH-UHFFFAOYSA-N 3,5-dimethylhex-1-yn-3-ol Chemical compound CC(C)CC(C)(O)C#C NECRQCBKTGZNMH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010061711 Gliadin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010052143 Ocular discomfort Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000271897 Viperidae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003486 chemical etching Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007688 edging Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 2
- 229940012664 nevanac Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920005643 polyisobutyl cyanoacrylate Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 2
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000007776 silk screen coating Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical compound CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical class CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920004142 LEXAN™ Polymers 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000004418 Lexan Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002724 Poly(ethyl cyanoacrylate) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940112258 acular Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000002717 carbon nanostructure Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940069275 cosopt Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013036 cure process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- PHZBCJRXGMUEJI-UHFFFAOYSA-N ethene;propane-1,2,3-triol Chemical compound C=C.C=C.OCC(O)CO PHZBCJRXGMUEJI-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000016339 iris pattern Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229940080267 lotemax Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229960001963 pilocarpine nitrate Drugs 0.000 description 1
- 238000007517 polishing process Methods 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 229940000148 polytrim Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000010106 rotational casting Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001029 thermal curing Methods 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Polymers COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- XAASNKQYFKTYTR-UHFFFAOYSA-N tris(trimethylsilyloxy)silicon Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)O[Si](C)(C)C XAASNKQYFKTYTR-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
- C08L33/08—Homopolymers or copolymers of acrylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
- C08L33/10—Homopolymers or copolymers of methacrylic acid esters
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Eyeglasses (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Laminated Bodies (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34182410P | 2010-04-03 | 2010-04-03 | |
| US341824P | 2010-04-03 | ||
| PCT/US2011/000593 WO2011123180A1 (en) | 2010-04-03 | 2011-04-02 | Medical devices including medicaments and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2634551T3 true ES2634551T3 (es) | 2017-09-28 |
Family
ID=44709947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11763185.3T Active ES2634551T3 (es) | 2010-04-03 | 2011-04-02 | Métodos para revestir una lente de contacto |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9931296B2 (enExample) |
| EP (2) | EP2555751B8 (enExample) |
| JP (4) | JP2013524275A (enExample) |
| AU (1) | AU2011233663B2 (enExample) |
| CA (1) | CA2794956C (enExample) |
| ES (1) | ES2634551T3 (enExample) |
| NZ (1) | NZ602673A (enExample) |
| SG (1) | SG184244A1 (enExample) |
| WO (1) | WO2011123180A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| GB2455962A (en) | 2007-12-24 | 2009-07-01 | Ethicon Inc | Reinforced adhesive backing sheet, for plaster |
| BRPI0906095A2 (pt) | 2008-03-05 | 2016-06-21 | Kci Licensing Inc | curativo com pressão reduzida para aplicar um tratamento com pressão reduzida a um sítio tecidual, método para coletar fluido em um curativo posicionado em um sítio tecidual e curativo com pressão reduzida adaptado para distribuir uma pressão reduzida a um sítio tecidual. |
| CA2979355C (en) | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| IT1398443B1 (it) * | 2010-02-26 | 2013-02-22 | Lima Lto S P A Ora Limacorporate Spa | Elemento protesico integrato |
| US8814842B2 (en) | 2010-03-16 | 2014-08-26 | Kci Licensing, Inc. | Delivery-and-fluid-storage bridges for use with reduced-pressure systems |
| US10413506B2 (en) | 2010-04-03 | 2019-09-17 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
| WO2011123180A1 (en) | 2010-04-03 | 2011-10-06 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
| US10414839B2 (en) | 2010-10-20 | 2019-09-17 | Sirrus, Inc. | Polymers including a methylene beta-ketoester and products formed therefrom |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| GB2488749A (en) * | 2011-01-31 | 2012-09-12 | Systagenix Wound Man Ip Co Bv | Laminated silicone coated wound dressing |
| GB201106491D0 (en) | 2011-04-15 | 2011-06-01 | Systagenix Wound Man Ip Co Bv | Patterened silicone coating |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US9381154B2 (en) * | 2011-06-09 | 2016-07-05 | Xerox Corporation | Direct inkjet fabrication of drug delivery devices |
| EP3339301A3 (en) | 2011-10-19 | 2018-08-08 | Sirrus, Inc. | Methods for making methylene beta-diketone monomers |
| US8414654B1 (en) * | 2011-11-23 | 2013-04-09 | Amendia, Inc. | Bone implants and method of manufacture |
| US10940047B2 (en) | 2011-12-16 | 2021-03-09 | Kci Licensing, Inc. | Sealing systems and methods employing a hybrid switchable drape |
| AU2012352000B2 (en) | 2011-12-16 | 2017-06-29 | Solventum Intellectual Properties Company | Releasable medical drapes |
| US10913875B2 (en) | 2012-03-30 | 2021-02-09 | Sirrus, Inc. | Composite and laminate articles and polymerizable systems for producing the same |
| EP3626784A1 (en) | 2012-03-30 | 2020-03-25 | Sirrus, Inc. | Ink and coating formulations and polymerizable systems for producing the same |
| US10047192B2 (en) | 2012-06-01 | 2018-08-14 | Sirrus, Inc. | Optical material and articles formed therefrom |
| US9089388B2 (en) * | 2012-07-06 | 2015-07-28 | Peter John Zegarelli | Oral appliance for delivery of medicaments and/or other substances |
| EP2890291B1 (en) | 2012-08-31 | 2020-06-24 | Volcano Corporation | Mounting structures for components of intravascular devices |
| US20140099351A1 (en) * | 2012-10-04 | 2014-04-10 | Axxia Pharmaceuticals, Llc | Process for making controlled release medical implant products |
| CN105008438B (zh) | 2012-11-16 | 2019-10-22 | 拜奥福米克斯公司 | 塑料粘结体系及方法 |
| AU2013344686B2 (en) | 2012-11-16 | 2018-06-21 | Solventum Intellectual Properties Company | Medical drape with pattern adhesive layers and method of manufacturing same |
| CN105164797B (zh) | 2012-11-30 | 2019-04-19 | 瑟拉斯公司 | 用于电子应用的复合组合物 |
| GB201222770D0 (en) | 2012-12-18 | 2013-01-30 | Systagenix Wound Man Ip Co Bv | Wound dressing with adhesive margin |
| WO2014161002A2 (en) * | 2013-03-29 | 2014-10-02 | Onefocus Technology, Llc | Drug delivery from contact lenses with a fluidic module |
| SG2013035662A (en) * | 2013-05-08 | 2014-12-30 | Menicon Singapore Pte Ltd | Systems and methods for printing on a contact lens |
| GB201310452D0 (en) | 2013-06-12 | 2013-07-24 | Blagdon Actuation Res Ltd | Fluid Manifolds |
| US9655715B2 (en) * | 2013-07-11 | 2017-05-23 | Tepha, Inc. | Absorbable implants for plastic surgery |
| KR101726473B1 (ko) | 2013-08-21 | 2017-04-26 | 주식회사 스탠딩에그 | 단결정 실리콘의 마이크로머시닝 기법에서 불순물 확산을 이용한 절연방법 |
| US10117978B2 (en) | 2013-08-26 | 2018-11-06 | Kci Licensing, Inc. | Dressing interface with moisture controlling feature and sealing function |
| US10946124B2 (en) | 2013-10-28 | 2021-03-16 | Kci Licensing, Inc. | Hybrid sealing tape |
| US9925092B2 (en) | 2013-10-30 | 2018-03-27 | Kci Licensing, Inc. | Absorbent conduit and system |
| EP3513773A1 (en) | 2013-10-30 | 2019-07-24 | KCI Licensing, Inc. | Condensate absorbing and dissipating system |
| EP3821859A1 (en) | 2013-10-30 | 2021-05-19 | 3M Innovative Properties Co. | Dressing with differentially sized perforations |
| WO2015065616A1 (en) | 2013-10-30 | 2015-05-07 | Kci Licensing, Inc. | Dressing with sealing and retention intereface |
| EP3848009B1 (en) | 2014-02-28 | 2025-07-23 | Solventum Intellectual Properties Company | Hybrid drape having a gel-coated perforated mesh |
| US11026844B2 (en) | 2014-03-03 | 2021-06-08 | Kci Licensing, Inc. | Low profile flexible pressure transmission conduit |
| AU2015234581B2 (en) * | 2014-03-25 | 2018-06-21 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
| EP3137029B1 (en) | 2014-05-02 | 2020-09-09 | KCI Licensing, Inc. | Fluid storage devices, systems, and methods |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| AU2015269359B2 (en) | 2014-06-05 | 2019-08-15 | Kci Licensing, Inc. | Dressing with fluid acquisition and distribution characteristics |
| CN104691201A (zh) * | 2014-11-05 | 2015-06-10 | 杭州安费诺飞凤通信部品有限公司 | 蓝宝石玻璃片装饰加工工艺 |
| US9844930B2 (en) | 2014-11-05 | 2017-12-19 | Xerox Corporation | 3D printing of digestible shells for medicaments |
| RU2585746C1 (ru) * | 2014-11-17 | 2016-06-10 | Федеральное государственное бюджетное военное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) | Способ создания лечебной мягкой контактной линзы |
| US10398604B2 (en) | 2014-12-17 | 2019-09-03 | Kci Licensing, Inc. | Dressing with offloading capability |
| HUE046267T2 (hu) * | 2015-01-21 | 2020-02-28 | Bayer Oy | Nem szteroid gyulladáscsökkentõ (NSAID) és progesztogén vegyületet tartalmazó gyógyszerbeviteli rendszer és elõállítási eljárások |
| US20180085974A1 (en) * | 2015-03-19 | 2018-03-29 | Palram Industries (1990) Ltd. | Auto clean surface and method of making same |
| CN106137764A (zh) * | 2015-03-27 | 2016-11-23 | 上海时代天使医疗器械有限公司 | 具有储药结构的牙科器械及其制造方法 |
| US11246975B2 (en) | 2015-05-08 | 2022-02-15 | Kci Licensing, Inc. | Low acuity dressing with integral pump |
| US9334430B1 (en) | 2015-05-29 | 2016-05-10 | Sirrus, Inc. | Encapsulated polymerization initiators, polymerization systems and methods using the same |
| US9217098B1 (en) | 2015-06-01 | 2015-12-22 | Sirrus, Inc. | Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound |
| EP3741335B1 (en) | 2015-09-01 | 2023-05-24 | KCI Licensing, Inc. | Dressing with increased apposition force |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US10973694B2 (en) | 2015-09-17 | 2021-04-13 | Kci Licensing, Inc. | Hybrid silicone and acrylic adhesive cover for use with wound treatment |
| KR101708683B1 (ko) * | 2015-09-23 | 2017-02-21 | 서강대학교 산학협력단 | 서방형 약물 방출 콘텍트렌즈 |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| EP4411037A3 (en) | 2015-12-22 | 2024-11-06 | Access Vascular, Inc. | High strength biomedical materials |
| CN115120405A (zh) | 2016-04-20 | 2022-09-30 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
| CN109843229A (zh) * | 2016-09-30 | 2019-06-04 | 领视药公司 | 借助双域眼用装置的高精确度药物递送 |
| CN106491551A (zh) * | 2016-11-17 | 2017-03-15 | 暨南大学 | 一种3d打印多层控释药片及其制备方法 |
| US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
| KR102290262B1 (ko) * | 2017-03-24 | 2021-08-13 | 이 잉크 캘리포니아 엘엘씨 | 활성 분자들을 전달하기 위한 마이크로셀 시스템들 |
| JP2018194811A (ja) * | 2017-05-12 | 2018-12-06 | 株式会社プラスアルファー | コンタクトレンズ |
| JP2020525097A (ja) | 2017-06-21 | 2020-08-27 | アクセス・バスキュラー・インコーポレイテッドＡｃｃｅｓｓ Ｖａｓｃｕｌａｒ， Ｉｎｃ． | 水溶性ポリマーを組み込んだ高強度ポーラス状材 |
| WO2019048986A1 (en) * | 2017-09-08 | 2019-03-14 | Sabic Global Technologies B.V. | METHOD OF MANUFACTURING A POLYCARBONATE ARTICLE |
| EP3709972B1 (en) * | 2017-11-14 | 2022-03-30 | E Ink California, LLC | Electrophoretic active delivery system including porous conductive electrode layer |
| CN107823702A (zh) * | 2017-11-17 | 2018-03-23 | 迈海新型材料科技（固安）有限公司 | 一种3d打印人工骨的制造方法 |
| CN107670117A (zh) * | 2017-11-17 | 2018-02-09 | 迈海新型材料科技（固安）有限公司 | 一种3d打印人工骨的制造方法 |
| CN107670118A (zh) * | 2017-11-17 | 2018-02-09 | 迈海新型材料科技（固安）有限公司 | 一种3d打印人工骨的制造方法 |
| MX2020010168A (es) * | 2018-03-28 | 2021-03-09 | Benjamin Lund | Polímeros de triol-acrilato, métodos de síntesis de los mismos y uso en tecnologías de fabricación por adición. |
| KR20210025601A (ko) * | 2018-06-29 | 2021-03-09 | 존슨 앤드 존슨 컨수머 인코포레이티드 | 활성제의 전달을 위한 3차원 미세유체학 장치 |
| WO2020009760A1 (en) * | 2018-07-03 | 2020-01-09 | ClearVision Sciences, Inc. | Methods of forming contact lenses to contain bioactive agents |
| US12194198B2 (en) * | 2018-12-19 | 2025-01-14 | Access Vascular, Inc. | High strength porous materials for controlled release |
| US11779739B2 (en) * | 2018-12-21 | 2023-10-10 | Perfect Ip, Llc | Drug delivery system and method |
| KR20220065759A (ko) * | 2019-07-23 | 2022-05-20 | 어댑티브 3디 테크놀로지스 엘엘씨 | 3d 프린팅을 위한 티올-아크릴레이트 엘라스토머 |
| MX2022005647A (es) | 2019-11-14 | 2022-09-07 | Swimc Llc | Composiciones de revestimiento en polvo para envasados metalicos, sustratos metalicos revestidos y metodos. |
| JP7438346B2 (ja) | 2019-11-27 | 2024-02-26 | イー インク コーポレイション | 電気浸食シール層を有するマイクロセルを備えている有益剤送達システム |
| EP3848179A1 (de) | 2020-01-10 | 2021-07-14 | Carl Zeiss Vision International GmbH | Inkjet-verfahren zur herstellung eines brillenglases |
| US20210220171A1 (en) * | 2020-01-16 | 2021-07-22 | University Of Florida Research Foundation, Inc. | Microbead And Nanofiber Based Controlled Drug Release System |
| GB202008098D0 (en) | 2020-05-29 | 2020-07-15 | Uea Enterprises Ltd | A method of coating an ocular prosthetic device and other prosthetics |
| CN115989054A (zh) | 2020-06-30 | 2023-04-18 | 阿塞斯血管有限公司 | 包含标记的制品和相关方法 |
| WO2022093541A1 (en) | 2020-10-29 | 2022-05-05 | E Ink California, Llc | Microcell systems for delivering benefit agents |
| JP7521119B2 (ja) | 2020-10-29 | 2024-07-23 | イー インク コーポレイション | 親水性活性分子を送達するためのマイクロセルシステム |
| EP4416495A4 (en) * | 2021-10-15 | 2025-09-03 | California Inst Of Techn | METHODS AND SYSTEMS FOR MANUFACTURING BIOSENSORS |
| US12498590B2 (en) | 2022-04-28 | 2025-12-16 | Johnson & Johnson Vision Care, Inc. | Using particles for light filtering |
| US20230348718A1 (en) * | 2022-04-28 | 2023-11-02 | Johnson & Johnson Vision Care, Inc. | Light-filtering materials for biomaterial integration and methods thereof |
| EP4555375A1 (en) | 2022-07-15 | 2025-05-21 | Praful Doshi | Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs |
| WO2025090976A1 (en) * | 2023-10-26 | 2025-05-01 | Atheneum Optical Sciences, Llc | Precision control of placement of items in an ophthalmic device |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2976576A (en) | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
| US3220960A (en) | 1960-12-21 | 1965-11-30 | Wichterle Otto | Cross-linked hydrophilic polymers and articles made therefrom |
| US3431046A (en) | 1964-02-14 | 1969-03-04 | Studies Inc | Flexible polyethylene corneal contact lens |
| US3503942A (en) | 1965-10-23 | 1970-03-31 | Maurice Seiderman | Hydrophilic plastic contact lens |
| US3557261A (en) | 1967-10-05 | 1971-01-19 | Ceskoslovenska Akademie Ved | Method of centrifugally casting layered contact lenses |
| US3536386A (en) | 1967-10-27 | 1970-10-27 | Morris Spivack | Contact lens with simulated iris |
| US3542461A (en) | 1967-11-20 | 1970-11-24 | Du Pont | Contact lens having an index of refraction approximating that of human tears |
| US3621079A (en) | 1968-10-21 | 1971-11-16 | Patent Structures Inc | Graft of hydroxyalkyl methacrylate onto polyvinylpyrrolidone |
| US3532679A (en) | 1969-04-07 | 1970-10-06 | Robert Steckler | Hydrogels from cross-linked polymers of n-vinyl lactams and alkyl acrylates |
| US3618604A (en) | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3639524A (en) | 1969-07-28 | 1972-02-01 | Maurice Seiderman | Hydrophilic gel polymer insoluble in water from polyvinylpyrrolidone with n-vinyl-2-pyrrolidone and methacrylic modifier |
| BE759530A (fr) | 1969-11-28 | 1971-04-30 | Griffin Lab Inc | Lentille de contact et son procede de fabrication |
| US3816571A (en) | 1969-11-28 | 1974-06-11 | Warner Lambert Co | Fabrication of soft plastic lens |
| US3712718A (en) | 1970-10-23 | 1973-01-23 | J Legrand | Corneal contact lens |
| US3803093A (en) | 1971-02-25 | 1974-04-09 | C Neefe | Methyl methacrylate copolymer which may be hydrated |
| US3940207A (en) | 1971-06-11 | 1976-02-24 | E. I. Du Pont De Nemours And Company | Soft, tough low refractive index contact lenses |
| US3772235A (en) | 1971-10-05 | 1973-11-13 | Union Optics Corp | Copolymers and hydrogels of unsaturated heterocyclic compounds |
| US3758448A (en) | 1971-10-05 | 1973-09-11 | Union Optics Corp | Copolymers and hydrogels of unsaturated esters |
| US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
| US4055378A (en) | 1971-12-31 | 1977-10-25 | Agfa-Gevaert Aktiengesellschaft | Silicone contact lens with hydrophilic surface treatment |
| US3786812A (en) | 1972-03-10 | 1974-01-22 | C Neefe | Contact lens for olar drug delivery |
| US3948871A (en) | 1972-04-21 | 1976-04-06 | George H. Butterfield And Son | Composition for hard type contact lens with wettable surface |
| US3786034A (en) | 1972-06-23 | 1974-01-15 | Frigitronics Of Conn Inc | Polyurethane polymers for use in soft lenses and method of producing soft lenses |
| US3875211A (en) | 1973-01-22 | 1975-04-01 | Alcolac Inc | Process for preparing 2-hydroxyalkylacrylates and 2-hydroxyalkylmethacrylates |
| US3937680A (en) | 1973-05-29 | 1976-02-10 | Global Vision, Inc. | Hydrophilic gel terpolymers from hydrophilic n-vinyl monomers, hydroxyalkyl acrylates or methacrylates and polymerizable unsaturated carboxylic acids |
| JPS5510050B2 (enExample) | 1973-08-13 | 1980-03-13 | ||
| JPS5337028B2 (enExample) | 1973-12-11 | 1978-10-06 | ||
| JPS543738B2 (enExample) | 1974-05-27 | 1979-02-26 | ||
| US4018853A (en) | 1974-11-21 | 1977-04-19 | Warner-Lambert Company | Crosslinked, hydrophilic rods of pyrrolidone-methacrylate graft copolymers |
| FR2292989A1 (fr) | 1974-11-29 | 1976-06-25 | Thomson Csf | Connecteur pour fibre optique |
| US4064086A (en) | 1976-07-13 | 1977-12-20 | National Patent Development Corporation | Thermoplastic hydrogels |
| JPS5770816A (en) * | 1980-10-17 | 1982-05-01 | Ono Pharmaceut Co Ltd | Multilayered film preparation of prostagladin of prolonged action |
| US4793264A (en) | 1981-12-07 | 1988-12-27 | Dataproducts Corporation | Low corrosion impulse ink jet ink containing anti-oxidant |
| US4558931A (en) | 1982-04-02 | 1985-12-17 | Color Optics, Ltd. (Partnership) | Colored soft contact lens |
| US4582402A (en) | 1984-04-16 | 1986-04-15 | Schering Corporation | Color-imparting contact lenses |
| US4704017A (en) | 1984-04-16 | 1987-11-03 | Schering Corporation | Process for manufacturing colored contact lenses |
| US4668240A (en) | 1985-05-03 | 1987-05-26 | Schering Corporation | Pigment colored contact lenses and method for making same |
| US5106182A (en) | 1986-02-24 | 1992-04-21 | Briggs Charles R | Laminated cosmetic contact lens and method of making same |
| US4925581A (en) | 1988-07-19 | 1990-05-15 | International Lubricants, Inc. | Meadowfoam oil and meadowfoam oil derivatives as lubricant additives |
| US5034166A (en) | 1988-07-21 | 1991-07-23 | Allergan, Inc. | Method of molding a colored contact lens |
| AR248194A1 (es) | 1988-09-02 | 1995-06-30 | Pfoertner Cornealent S A C I F | Lentes de contacto capaces de modificar el color perceptible del iris del usuario y procedimiento para fabricarlos. |
| US4898695A (en) | 1988-11-01 | 1990-02-06 | Pilkington Visioncare Holdings, Inc. | Method for tinting hydrophilic plastic articles |
| US5018849A (en) | 1988-11-16 | 1991-05-28 | Ciba-Geigy Corporation | Colored contact lens and methods of making the same |
| CA2051387C (en) | 1989-04-14 | 1996-06-25 | Michael H. Quinn | Color binding mechanism for contact lenses |
| ATE120560T1 (de) | 1989-11-01 | 1995-04-15 | Schering Corp | Kontaktlinse mit natürlichem erscheinen. |
| US5227372A (en) | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
| DE4134526A1 (de) | 1990-10-18 | 1992-05-14 | Toyo Gosei Kogyo Kk | Positive photoresist-zusammensetzung und mustererzeugungsverfahren unter verwendung dieser zusammensetzung |
| US5160463A (en) | 1990-10-30 | 1992-11-03 | Pilkington Visioncare, Inc. | Method of manufacturing a contact lens |
| AU669332B2 (en) | 1991-05-09 | 1996-06-06 | Hydron Limited | Pad printing coating composition and printing process |
| US5270051A (en) * | 1991-10-15 | 1993-12-14 | Harris Donald H | Enzyme-orthokeratology |
| US5271765A (en) * | 1992-02-03 | 1993-12-21 | E. I. Du Pont De Nemours And Company | Aqueous cationic dye-based ink jet inks |
| US5296228A (en) | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
| US5271874A (en) | 1992-11-04 | 1993-12-21 | Wesley-Jessen Corporation | Method for molding a hydrophilic contact lens |
| US5352245A (en) | 1992-11-20 | 1994-10-04 | Ciba-Geigy Corporation | Process for tinting contact lens |
| US6743438B2 (en) | 1993-10-26 | 2004-06-01 | Pbh, Inc. | Colored contact lenses and method of making same |
| US5578638A (en) | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| WO1995015748A1 (en) | 1993-12-08 | 1995-06-15 | Vitaphore Corporation | Microsphere drug delivery system |
| US5389132A (en) | 1994-02-02 | 1995-02-14 | Jetfill, Inc. | Thermal ink-jet exhibiting reduced kogation |
| US5480914A (en) | 1994-05-06 | 1996-01-02 | Allergan, Inc. | Nonaqueous thixotropic drug delivery suspensions and methods of their use |
| JP3107726B2 (ja) * | 1994-05-13 | 2000-11-13 | 株式会社クラレ | 水膨潤性高分子ゲル |
| US5452658A (en) | 1994-07-20 | 1995-09-26 | Diversified Decorating Sales, Inc. | Pad transfer printing pads for use with contact lenses |
| JP3542425B2 (ja) | 1994-11-17 | 2004-07-14 | キヤノン株式会社 | インクジェット記録用水系分散インク、これを用いるインクジェット記録方法、インクカートリッジ、記録ユニットおよび記録装置 |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5560766A (en) | 1995-06-07 | 1996-10-01 | Xerox Corporation | Thermal ink jet composition |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| US6678553B2 (en) | 1995-11-21 | 2004-01-13 | Intraabrain International Nv | Device for enhanced delivery of biologically active substances and compounds in an organism |
| US5900407A (en) | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US5905561A (en) | 1996-06-14 | 1999-05-18 | Pbh, Inc. | Annular mask lens having diffraction reducing edges |
| US5662706A (en) | 1996-06-14 | 1997-09-02 | Pbh, Inc. | Variable transmissivity annular mask lens for the treatment of optical aberrations |
| US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| GB9616672D0 (en) | 1996-08-08 | 1996-09-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| TW519535B (en) | 1996-12-06 | 2003-02-01 | Nippon Catalytic Chem Ind | Higher secondary alcohol alkoxylate compound composition, method for production thereof, and detergent and emulsifier using the composition |
| WO1998036738A1 (en) * | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| CA2286590C (en) * | 1997-04-18 | 2005-08-02 | California Institute Of Technology | Multifunctional polymeric tissue coatings |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US6335335B2 (en) | 1997-11-05 | 2002-01-01 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
| WO1999024019A1 (en) | 1997-11-06 | 1999-05-20 | Orbon Corporation | Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same |
| FR2773320B1 (fr) | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| DE69904465T2 (de) * | 1998-05-14 | 2003-10-02 | Alza Corp., Mountain View | Therapie von depressionen |
| WO2004073708A1 (en) | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| US6410045B1 (en) | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
| US6217896B1 (en) | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
| US6319240B1 (en) | 1999-05-25 | 2001-11-20 | Iomed, Inc. | Methods and apparatus for ocular iontophoresis |
| US6539251B2 (en) | 1999-05-25 | 2003-03-25 | Iomed, Inc. | Ocular iontophoretic apparatus |
| US7048375B2 (en) | 1999-11-01 | 2006-05-23 | Praful Doshi | Tinted lenses and methods of manufacture |
| EP1226465B1 (en) | 1999-11-01 | 2006-01-11 | Praful Doshi | Tinted polymer contact lens and method of manufacturing the same |
| US7267846B2 (en) | 1999-11-01 | 2007-09-11 | Praful Doshi | Tinted lenses and methods of manufacture |
| US6880932B2 (en) * | 1999-11-01 | 2005-04-19 | Praful Doshi | Tinted lenses and methods of manufacture |
| CA2389917A1 (en) | 1999-11-04 | 2001-05-10 | Kazunori Kataoka | A polymer micelle as monolayer or layer-laminated surface |
| US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
| US6811259B2 (en) | 2000-06-12 | 2004-11-02 | Novartis Ag | Printing colored contact lenses |
| CN1441679A (zh) | 2000-07-14 | 2003-09-10 | 阿勒根公司 | 包含具有提高的溶解度的治疗活性组分的组合物 |
| AU2001271417B2 (en) | 2000-08-30 | 2006-10-05 | Johns Hopkins University | Devices for intraocular drug delivery |
| US6579519B2 (en) | 2000-09-18 | 2003-06-17 | Registrar, University Of Delhi | Sustained release and long residing ophthalmic formulation and the process of preparing the same |
| US6703039B2 (en) | 2000-12-06 | 2004-03-09 | Bausch & Lomb Incorporated | Reversible gelling system for ocular drug delivery |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6827966B2 (en) * | 2001-05-30 | 2004-12-07 | Novartis Ag | Diffusion-controllable coatings on medical device |
| US20030185892A1 (en) | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
| US7300668B2 (en) | 2001-10-29 | 2007-11-27 | Massachusetts Institute Of Technology | System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing |
| EP1439824A2 (en) | 2001-10-29 | 2004-07-28 | Therics, Inc. | Three-dimensional suspension printing of dosage forms |
| WO2003103549A1 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Ophthalmic drug delivery system |
| US8071121B2 (en) | 2002-06-05 | 2011-12-06 | University Of Florida Research Foundation, Incorporated | Dispersions of microemulsions in hydrogels for drug delivery |
| US7655038B2 (en) * | 2003-02-28 | 2010-02-02 | Biointeractions Ltd. | Polymeric network system for medical devices and methods of use |
| ATE370998T1 (de) * | 2002-06-26 | 2007-09-15 | Mars Inc | Essbare tinten f r tintenstrahldruck auf essbaren substraten |
| EP1605862A4 (en) * | 2003-02-28 | 2008-09-03 | Fibrogen Inc | COLLAGEN COMPOSITIONS AND BIOMATERIALS |
| US20040219195A1 (en) * | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| JP2005218780A (ja) * | 2004-02-09 | 2005-08-18 | Menicon Co Ltd | 薬物放出速度を制御し得る薬物徐放可能なヒドロゲル材料の製造方法 |
| US8163269B2 (en) * | 2004-04-05 | 2012-04-24 | Carpenter Kenneth W | Bioactive stents for type II diabetics and methods for use thereof |
| US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| JP2008505991A (ja) * | 2004-05-18 | 2008-02-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 半導電性ポリマーを含むインクジェット印刷用の配合物 |
| US8535702B2 (en) * | 2005-02-01 | 2013-09-17 | Boston Scientific Scimed, Inc. | Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility |
| WO2006082221A1 (en) * | 2005-02-03 | 2006-08-10 | Cinvention Ag | Drug delivery materials made by sol/gel technology |
| KR101484499B1 (ko) * | 2005-02-14 | 2015-01-20 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈 |
| ES2986867T3 (es) * | 2005-03-03 | 2024-11-12 | Mirus Llc | Aleaciones metálicas mejoradas para dispositivos médicos |
| JP2008538754A (ja) * | 2005-04-11 | 2008-11-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 薬剤を含んだ所定のレイヤパターンを有する複層構造体 |
| US20060259008A1 (en) | 2005-04-27 | 2006-11-16 | Allergan, Inc. | Apparatus and methods useful for intravitreal injection of drugs |
| US9804295B2 (en) * | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| US20060281986A1 (en) | 2005-06-09 | 2006-12-14 | Allergan, Inc. | Apparatus and methods useful for monitoring intraocular pressure |
| US20070178133A1 (en) * | 2005-11-09 | 2007-08-02 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
| JPWO2007105691A1 (ja) | 2006-03-13 | 2009-07-30 | 株式会社アールテック・ウエノ | 水性組成物 |
| US20080097335A1 (en) | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US20080062381A1 (en) * | 2006-09-13 | 2008-03-13 | Praful Doshi | Tinted lenses and methods of manufacture |
| US20080075753A1 (en) * | 2006-09-25 | 2008-03-27 | Chappa Ralph A | Multi-layered coatings and methods for controlling elution of active agents |
| US20080107713A1 (en) | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| CA2689675A1 (en) | 2007-02-07 | 2008-08-14 | Mcgill University | Bioceramic implants having bioactive substance |
| US20080317819A1 (en) | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
| TW200912348A (en) | 2007-06-22 | 2009-03-16 | Phicom Corp | Electric inspection apparatus |
| US20090004244A1 (en) | 2007-06-27 | 2009-01-01 | Orilla Werhner C | Iris design as a drug depot for zonal drug delivery by contact lens |
| US20090004245A1 (en) | 2007-06-28 | 2009-01-01 | Orilla Werhner C | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens |
| US20090041824A1 (en) * | 2007-08-07 | 2009-02-12 | Arsenal Medical, Inc. | Method and apparatus for composite drug delivery medical devices |
| US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
| US20090082796A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Modified tenotomy scissors with conjunctiva risers |
| US8353862B2 (en) | 2007-11-02 | 2013-01-15 | Allergan, Inc. | Drug delivery systems and methods |
| WO2009123624A1 (en) | 2008-04-01 | 2009-10-08 | Hewlett-Packard Development Company, L.P. | Method and system for coating an article |
| US20090274740A1 (en) | 2008-05-01 | 2009-11-05 | Boston Scientific Scimed, Inc. | Drug-loaded medical devices and methods for manufacturing drug-loaded medical devices |
| US20090281433A1 (en) | 2008-05-07 | 2009-11-12 | Sonitus Medical, Inc. | Systems and methods for pulmonary monitoring and treatment |
| US20100036482A1 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of manufacturing thereof |
| US8414912B2 (en) | 2008-12-11 | 2013-04-09 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
| US20100247606A1 (en) | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| WO2011123180A1 (en) | 2010-04-03 | 2011-10-06 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
-
2011
- 2011-04-02 WO PCT/US2011/000593 patent/WO2011123180A1/en not_active Ceased
- 2011-04-02 NZ NZ602673A patent/NZ602673A/en unknown
- 2011-04-02 CA CA2794956A patent/CA2794956C/en active Active
- 2011-04-02 EP EP11763185.3A patent/EP2555751B8/en active Active
- 2011-04-02 EP EP17159664.6A patent/EP3195858B1/en active Active
- 2011-04-02 ES ES11763185.3T patent/ES2634551T3/es active Active
- 2011-04-02 JP JP2013502569A patent/JP2013524275A/ja active Pending
- 2011-04-02 AU AU2011233663A patent/AU2011233663B2/en active Active
- 2011-04-02 SG SG2012070918A patent/SG184244A1/en unknown
- 2011-04-02 US US13/065,904 patent/US9931296B2/en active Active
-
2015
- 2015-05-18 JP JP2015101314A patent/JP2015232707A/ja active Pending
-
2016
- 2016-12-27 JP JP2016254508A patent/JP2017107216A/ja active Pending
-
2018
- 2018-02-08 US US15/891,456 patent/US10045938B2/en active Active
- 2018-02-16 US US15/898,329 patent/US10076493B2/en active Active
- 2018-06-29 US US16/023,156 patent/US10188604B2/en active Active
- 2018-08-21 JP JP2018155030A patent/JP2019034153A/ja active Pending
- 2018-10-12 US US16/158,587 patent/US10369099B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180338912A1 (en) | 2018-11-29 |
| AU2011233663A1 (en) | 2012-10-18 |
| US20190046435A1 (en) | 2019-02-14 |
| EP2555751B8 (en) | 2018-02-14 |
| NZ602673A (en) | 2014-09-26 |
| US20180193258A1 (en) | 2018-07-12 |
| US20180193257A1 (en) | 2018-07-12 |
| US9931296B2 (en) | 2018-04-03 |
| JP2013524275A (ja) | 2013-06-17 |
| US10188604B2 (en) | 2019-01-29 |
| WO2011123180A4 (en) | 2012-02-16 |
| WO2011123180A1 (en) | 2011-10-06 |
| JP2015232707A (ja) | 2015-12-24 |
| JP2019034153A (ja) | 2019-03-07 |
| EP2555751A4 (en) | 2014-05-14 |
| JP2017107216A (ja) | 2017-06-15 |
| CA2794956A1 (en) | 2011-10-06 |
| US10369099B2 (en) | 2019-08-06 |
| EP3195858A1 (en) | 2017-07-26 |
| US20110244010A1 (en) | 2011-10-06 |
| EP3195858B1 (en) | 2019-08-07 |
| US10076493B2 (en) | 2018-09-18 |
| AU2011233663B2 (en) | 2016-04-14 |
| EP2555751B1 (en) | 2017-05-31 |
| EP2555751A1 (en) | 2013-02-13 |
| SG184244A1 (en) | 2012-11-29 |
| US10045938B2 (en) | 2018-08-14 |
| CA2794956C (en) | 2017-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2634551T3 (es) | Métodos para revestir una lente de contacto | |
| US11510869B2 (en) | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia | |
| US20240075268A1 (en) | Macroporous solid hard microneedles with embedded particulate drugs | |
| US11173130B2 (en) | Drug delivery system and methods of use | |
| Mittal et al. | Hydrogel breakthroughs in biomedicine: Recent advances and implications | |
| US12178904B2 (en) | Contact lenses including medicaments and methods of making and using same including stabilizers of labile components such as drugs | |
| Kim et al. | Contact lens with Ph sensitivity for on-demand drug release in wearing situation | |
| Gao et al. | Drug-eluting contact lenses: Progress, challenges, and prospects | |
| WO2024254134A2 (en) | Contact lenses including medicaments and methods of making and using same including slow release of glaucoma treating drugs and comfort enhancing drugs | |
| Bagmar et al. | A Review on" Ocuserts (An Ophthalmic Insert)” | |
| Kashyap et al. | Role of 3D printing in ophthalmic products | |
| Pingale et al. | Smart Polymers in Medicine | |
| WO2025090976A1 (en) | Precision control of placement of items in an ophthalmic device | |
| Prajapati | Polymers in Retinal Prosthesis | |
| Nazir et al. | Emerging fabrication strategies of hydrogel and its use as a drug delivery vehicle |